Multidrug resistance-associated protein 4 (ABCC4), an ATP-binding cassette transporter, and arachidonate 15-lipoxygenase B (ALOX15B), an enzyme involved in lipid metabolism and inflammation, have been known to decrease in prostate cancer and with tumor progression [177]. Here, ABCC4 is linked to neoplasm.